14 October 2014
A new antiviral drug called “Triasavirin” is expected to soon be put into production in the Urals; the biotech solution is believed to be based on an innovative technology of directly impacting a virus, the Skolkovo Foundation website reported . The Ural Center for Biopharma Technologies (UCBT), the developer of the solution, is a Skolkovo resident.
“Triasavirin” is reported to have been fine-tuned, tested and even approved by the Russian Ministry of Healthcare and is now a registered medicine in Russia.
“The “Triasaverin” molecule is focused directly on a virus. We unleash it to ‘deceive’ the root cause of the virus by ‘offering’ the intruder a flawed construction material, thus inhibiting its replication process. When the virus runs into the molecule, it absorbs it and loses its ability to multiply as a result,” said Gelena Lifshits, the head of biomed programs at Skolkovo.
According to Ms. Lifshits, UCBT appears to have proven the efficacy of the new drug in fighting “practically all known strains of flu and tick-borne encephalitis.” The developer continues research into its possible use against other viruses, including the ones responsible for the entire group of upper respiratory tract infections, she added.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
New breast cancer guidelines call for first mammogram at age 40 but stop short of annual screening
08 May 2024
WHO proposes recommendations for preventing nitrosamine contamination
07 May 2024
Batyr Berdyklychev is now head of the WHO office in Russia
07 May 2024
Russia expects more medical tourism due to the world’s first drug for ankylosing spondylitis
07 May 2024